MREO · Mereo BioPharma Group plc

Mereo BioPharma's Q1 2026 results showed significant improvement in net loss to $6.7 million from $12.9 million year-over-year, primarily due to a $3.3 million decrease in general and administrative expenses. This decline was driven by a $1.9 million reimbursement for ADR program costs and $1.4 million in delayed pre-commercial activities for setrusumab in Europe. R&D expenses increased modestly by $0.8 million to $4.7 million, reflecting higher setrusumab costs from Ultragenyx's manufacturing slot cancellations, partially offset by lower alvelestat preparation expenses post prior-year activities. CEO Denise Scots-Knight highlighted ongoing regulatory engagements for setrusumab in pediatric OI patients following Phase 3 data analyses, where primary fracture rate endpoints were missed but key secondary bone mineral density improvements and patient-reported outcomes achieved statistical significance, alongside a consistent safety profile. The company is advancing alvelestat toward a single Phase 3 trial in ~220 AATD-LD patients with region-specific endpoints (SGRQ for U.S., lung density for Europe), potentially starting within 6 months of a partnership close. Partner āshibio plans Phase 2 initiation for vantictumab in ADO2 by H2 2026. Cash position of $36.2 million supports operations through mid-2027 amid these milestones, with no changes to guidance and ordinary shares at 798 million (159.6 million ADS equivalents).